This was originally published by AJMC The bone marrow (BM) microenvironment is believed to play a key role in the evolution of monoclonal gammopathy...
Myeloma NZ
HealthTree® Launches HealthTree University for Multiple Myeloma Patients
This was originally posted by Cision PR Newswire SALT LAKE CITY, July 9, 2020 /PRNewswire/ -- HealthTree®, the first online portal...
FDA Places MELANI-01 Study for Multiple Myeloma on Hold After Safety Report Submission
This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on...
Patients with Multiple Myeloma and CHIP Face Worse Outcomes Following ASCT
However, when followed by immunomodulatory drugs, researchers found that autologous stem cell transplant can be safely used in this patient...
Once-weekly selinexor regimen extends PFS in pretreated multiple myeloma
This article was originally published by Healio Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly...
CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain
This article was originally published by AJMC There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to...
Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple...
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple...
Multiple myeloma triple therapy now on PBS
This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment...
Subcutaneous vs intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Background | Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and...
GNS Healthcare Launches In Silico Multiple Myeloma “Patient”
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have...
MRP a valuable risk assessment tool for newly diagnosed multiple myeloma
A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.